Drug Trial Radar · NCT01391325
Allopurinol Outcome Study
Last checked: Nov 20, 2026Latest source record: Jun 17, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,735
Actual
Start
Jul 2011
Primary completion
Jan 2013
Study completion Mar 2013
Sponsor
- Lead sponsor
- Ardea Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 12, 2011
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study of allopurinol in gout patients with hyperuricemia that will evaluate the safety and serum urate (sUA) lowering capability of allopurinol as a urate lowering therapy (ULT) for up to six months. Allopurinol will be dosed according to the local product label, at the discretion of the Investigator, to achieve an optimal, medically appropriate dose for each patient.
Conditions
- Gout
Interventions
AllopurinolDrug
Commercially available allopurinol 100 mg and 300 mg oral tablets will be prescribed by the Investigator according to the approved product label.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of AllopurinolTime frame: Every month for 6 months.
Locations
173 sites in 7 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Birmingham, Alabama
Site not named
Bringham, Alabama
Site not named
Calera, Alabama
Site not named
Huntsville, Alabama
Site not named
Mobile, Alabama
Site not named
Chandlers, Arizona
Site not named
Green Valley, Arizona
Site not named
Jonesboro, Arizona
Site not named
Phoenix, Arizona
Site not named
Phoenix, Arizona
Site not named
Tucson, Arizona
Site not named
Little Rock, Arkansas
Site not named
Little Rock, Arkansas
Site not named
Anaheim, California
Site not named
Carmichael, California
Site not named
Covina, California
Site not named
Hemet, California
Site not named
Irvine, California
Site not named
Los Angeles, California
Site not named
Mission Viejo, California
Site not named
Pasadena, California
Site not named
Sacramento, California
Site not named
San Diego, California
Site not named
San Ramon, California
Site not named
Santa Maria, California
Site not named
Weslake Village, California
Site not named
Denver, Colorado
Site not named
Englewood, Colorado
Site not named
Danbury, Connecticut
Site not named
Trumbull, Connecticut
Site not named
Brandenton, Florida
Site not named
Brandon, Florida
Site not named
Brooksville, Florida
Site not named
East Brandenton, Florida
Site not named
Fleming Island, Florida
Site not named
Jacksonville, Florida
Site not named
Jacksonville, Florida
Site not named
Jupiter, Florida
Site not named
Miami, Florida
Showing 40 of 173 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.